IL308169A - Purification method of antibody composition - Google Patents
Purification method of antibody compositionInfo
- Publication number
- IL308169A IL308169A IL308169A IL30816923A IL308169A IL 308169 A IL308169 A IL 308169A IL 308169 A IL308169 A IL 308169A IL 30816923 A IL30816923 A IL 30816923A IL 308169 A IL308169 A IL 308169A
- Authority
- IL
- Israel
- Prior art keywords
- antibody
- media
- glycosylation
- chromatography
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/16—Extraction; Separation; Purification by chromatography
- C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Immunology (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021079977 | 2021-05-10 | ||
| PCT/JP2022/019548 WO2022239704A1 (ja) | 2021-05-10 | 2022-05-06 | 抗体組成物の精製方法 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL308169A true IL308169A (en) | 2024-01-01 |
Family
ID=84029593
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL308169A IL308169A (en) | 2021-05-10 | 2022-05-06 | Purification method of antibody composition |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20240383945A1 (https=) |
| EP (1) | EP4353734A4 (https=) |
| JP (1) | JPWO2022239704A1 (https=) |
| KR (1) | KR20240005771A (https=) |
| CN (1) | CN117279929A (https=) |
| AU (1) | AU2022271741A1 (https=) |
| CA (1) | CA3219950A1 (https=) |
| IL (1) | IL308169A (https=) |
| TW (1) | TW202309062A (https=) |
| WO (1) | WO2022239704A1 (https=) |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS644947A (en) | 1987-06-29 | 1989-01-10 | Rohm Co Ltd | Consecutive recording method for video tape recorder |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| EP1739089A4 (en) | 2004-03-30 | 2007-05-02 | Hiroshi Yanagisawa | PROCESS FOR DISINTER SEPARATION |
| WO2008120801A1 (ja) | 2007-04-02 | 2008-10-09 | Kyowa Hakko Kirin Co., Ltd. | アンチトロンビン組成物の製造方法 |
| US9249182B2 (en) * | 2012-05-24 | 2016-02-02 | Abbvie, Inc. | Purification of antibodies using hydrophobic interaction chromatography |
| ES2665341T3 (es) * | 2012-10-03 | 2018-04-25 | Chiome Bioscience Inc. | Anticuerpo anti-DLK-1 humana con actividad antitumoral in vivo |
| WO2014145744A1 (en) * | 2013-03-15 | 2014-09-18 | Alder Biopharmaceuticals, Inc. | Antibody purification and purity monitoring |
| US20180327447A1 (en) * | 2015-11-18 | 2018-11-15 | Merck Patent Gmbh | Improved protein separation in ion exchange chromatography |
| CA3127174A1 (en) * | 2019-01-23 | 2020-07-30 | Daiichi Sankyo Company, Limited | Methods for purifying antibodies comprising of a process by using activated carbon materials |
| US20220177582A1 (en) * | 2019-03-13 | 2022-06-09 | Ichnos Sciences SA | Non-consensus glycosylation of bispecific antibodies |
| JP2021079977A (ja) | 2019-11-19 | 2021-05-27 | 凸版印刷株式会社 | 袋状容器の注出口ユニット |
-
2022
- 2022-05-06 JP JP2023520995A patent/JPWO2022239704A1/ja active Pending
- 2022-05-06 CA CA3219950A patent/CA3219950A1/en active Pending
- 2022-05-06 IL IL308169A patent/IL308169A/en unknown
- 2022-05-06 TW TW111117152A patent/TW202309062A/zh unknown
- 2022-05-06 KR KR1020237040492A patent/KR20240005771A/ko active Pending
- 2022-05-06 EP EP22807406.8A patent/EP4353734A4/en active Pending
- 2022-05-06 US US18/289,914 patent/US20240383945A1/en active Pending
- 2022-05-06 CN CN202280033860.8A patent/CN117279929A/zh active Pending
- 2022-05-06 WO PCT/JP2022/019548 patent/WO2022239704A1/ja not_active Ceased
- 2022-05-06 AU AU2022271741A patent/AU2022271741A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN117279929A (zh) | 2023-12-22 |
| CA3219950A1 (en) | 2022-11-17 |
| WO2022239704A1 (ja) | 2022-11-17 |
| TW202309062A (zh) | 2023-03-01 |
| EP4353734A1 (en) | 2024-04-17 |
| JPWO2022239704A1 (https=) | 2022-11-17 |
| AU2022271741A1 (en) | 2023-11-23 |
| EP4353734A4 (en) | 2025-05-21 |
| KR20240005771A (ko) | 2024-01-12 |
| US20240383945A1 (en) | 2024-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022256199B2 (en) | Bispecific anti-human CD20/human transferrin receptor antibodies and methods of use | |
| US20230060770A1 (en) | Cation exchange chromatography wash buffer | |
| KR102380315B1 (ko) | 폴리펩티드 다량체를 정제하기 위한 폴리펩티드의 개변방법 | |
| US20190062419A1 (en) | Protein purification methods to reduce acidic species | |
| JP2024099610A (ja) | ヘテロ二量体多重特異性抗体を精製するための方法 | |
| TR201808458T4 (tr) | FC-reseptör bazlı afinite kromatografisi. | |
| KR102390246B1 (ko) | 항체의 시험관내 글리코조작에 있어서의 효소의 재사용 | |
| JP2024059888A (ja) | 単量体モノクローナル抗体を精製する方法 | |
| JP7511542B2 (ja) | タンパク質複合体を特徴づけるための方法 | |
| JP2023545019A (ja) | タンパク質精製プロセスにおいて宿主細胞タンパク質含有量を減少させるための方法 | |
| KR20220002581A (ko) | 정제 플랫폼으로부터 수득된 조성물의 효소적 가수분해 활성 속도를 감소시키는 방법 | |
| US20240115701A1 (en) | Methods and compositions comprising an anti-ctla4 monoclonal antibody with reduced host cell proteins and increased polysorbate-80 stability | |
| US20240383945A1 (en) | Purification method of antibody composition | |
| CA3197930A1 (en) | Relative unpaired glycans in antibody production methods | |
| US20150361128A1 (en) | Methods of using ion exchange chromatography to control levels of high mannose glycoforms | |
| EP3515932B1 (en) | Complement factor based affinity chromatography | |
| US20250129117A1 (en) | Rapid purification of monoclonal antibody from in-process upstream cell culture material | |
| TW202607021A (zh) | 結合ｔｓｌｐ之抗體及使用方法 | |
| AU2024362809A1 (en) | Rapid purification of monoclonal antibody from in-process upstream cell culture material | |
| EA052830B1 (ru) | АНТИТЕЛА, СВЯЗЫВАЮЩИЕ ДОМЕН γC ФИБРИНА ИЛИ ФИБРИНОГЕНА ЧЕЛОВЕКА, И СПОСОБЫ ПРИМЕНЕНИЯ |